Intramuscular testosterone moderately increased lumbar bone density in men ; the results on femoral neck bone density are inconclusive .
Without bone fracture data , the available trials offer weak and indirect inferences about the clinical efficacy of testosterone on osteoporosis prevention and treatment in men
CONTEXT And rogen-deficient men are at increased risk of osteoporosis .
The extent to which testosterone can prevent and treat osteoporosis in men remains unclear .
Osteopenia in eugonadal men with acquired immune deficiency syndrome wasting syndrome.
Multiple endocrine and metabolic consequences of human immunodeficiency virus ( HIV ) infection exist that may contribute to  bone loss in men with the acquired immune deficiency syndrome ( AIDS ) wasting syndrome . Recent studies suggest that anabolic strategies can increase lean body mass in men with AIDS wasting . Prior studies have not examined the effects of anabolic agents on bone mineral density ( BMD ) or bone turnover in these men . To determine the effects of testosterone and progressive resistance training on BMD and bone turnover in eugonadal men with AIDS wasting , we r and omly assigned 54 eugonadal men with AIDS wasting ( weight < 90 % IBW or weight loss > 10 % from preillness baseline ) to receive either testosterone enanthate ( 200 mg/week , i m ) or placebo and to progressive resistance training ( 3 times/week ) or no training in a 2 x 2 factorial study design for 3 months . The BMD of the lumbar spine , proximal femur , and total body ; lean body mass ; and fat mass were measured by dual energy x-ray absorptiometry . Total body scans were repeated after 12 weeks of therapy . Baseline bone turnover and BMD were compared with those in 35 age-matched healthy non-HIV-infected control subjects . Compared with controls , lumbar spine BMD ( 1.021 + /- 0.018 vs. 1.084 + /- 0.025 g/cm(2 ) ; P = 0.04 ) and total hip BMD ( 0.951 + /- 0.017 vs. 1.070 + /- 0.019 g/cm(2 ) ; P < 0.0001 ) were reduced in men with AIDS wasting . T-scores were lower in men with AIDS wasting at the lumbar spine ( -0.62 + /- 0.17 vs. -0.07 + /- 0.23 , P = 0.05 ) and total hip ( -0.65 + /- 0.11 vs. + 0.20 + /- 0.014 , P < 0.0001 ) . Total hip T scores were less than -1.0 in 33 % of men with AIDS wasting . Neither the use of protease inhibitors nor the duration of protease inhibitors use correlated with BMD . Serum osteocalcin levels were lower ( 3.63 + /- 0.29 vs. 4.54 + /- 0.31 nmol/L ; P < 0.04 ) and urinary N-telopeptide excretion was higher ( 45.4 + /- 4.5 vs. 26.8 + /- 3.0 nmol BCE/mmol creatinine ; P = 0.004 ) in men with AIDS wasting than in controls . Lumbar spine BMD , as assessed on regional total body dual energy x-ray absorptiometry scan , increased over the 12-week treatment period in response to testosterone ( + 2.4 + /- 1.3 vs. -1.3 + /- 1.0 % , testosterone vs. placebo , respectively ; P = 0.02 ) , but not in response to training ( + 0.8 + /- 1.0 vs. + 0.4 + /- 1.3 % , training vs. no training ; P = 0.70 ) . Lumbar spine and total hip BMD are reduced in eugonadal men with AIDS wasting .  Biochemical markers of bone turnover suggest that bone formation and bone resorption are uncoupled in these men . Testosterone administration , but not resistance training , over 3 months increases lumbar spine BMD in eugonadal men with AIDS wasting
Intramuscular testosterone moderately increased lumbar bone density in men ; the results on femoral neck bone density are inconclusive .
Without bone fracture data , the available trials offer weak and indirect inferences about the clinical efficacy of testosterone on osteoporosis prevention and treatment in men
CONTEXT And rogen-deficient men are at increased risk of osteoporosis .
The extent to which testosterone can prevent and treat osteoporosis in men remains unclear .